Osteoporosis drug meets all primary end points

22 Feb 2016


Amgen and UCB have announced that their Fracture study in postmenopausal women with osteoporosis has shown Romosozumab reduces the incidence of clinical fractures.

Reuters


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story